These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

821 related articles for article (PubMed ID: 9392330)

  • 1. Isolated limb reperfusion with tumor necrosis factor and melphalan in patients with extremity melanoma after failure of isolated limb perfusion with chemotherapeutics.
    Bartlett DL; Ma G; Alexander HR; Libutti SK; Fraker DL
    Cancer; 1997 Dec; 80(11):2084-90. PubMed ID: 9392330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of repeat isolated limb perfusions with tumor necrosis factor alpha and melphalan for multiple in-transit metastases in patients with prior isolated limb perfusion failure.
    Grünhagen DJ; van Etten B; Brunstein F; Graveland WJ; van Geel AN; de Wilt JH; Eggermont AM
    Ann Surg Oncol; 2005 Aug; 12(8):609-15. PubMed ID: 15968498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone.
    Vrouenraets BC; Eggermont AM; Hart AA; Klaase JM; van Geel AN; Nieweg OE; Kroon BB
    Eur J Surg Oncol; 2001 Jun; 27(4):390-5. PubMed ID: 11417986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isolated limb perfusion for in-transit melanoma metastases: melphalan or TNF-melphalan perfusion?
    Hoekstra HJ; Veerman K; van Ginkel RJ
    J Surg Oncol; 2014 Mar; 109(4):338-47. PubMed ID: 24403098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Repeat isolated limb perfusion with TNFalpha and melphalan for recurrent limb melanoma after failure of previous perfusion.
    Noorda EM; Vrouenraets BC; Nieweg OE; van Geel AN; Eggermont AM; Kroon BB
    Eur J Surg Oncol; 2006 Apr; 32(3):318-24. PubMed ID: 16412605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isolated limb perfusion with the tumor-targeting human monoclonal antibody-cytokine fusion protein L19-TNF plus melphalan and mild hyperthermia in patients with locally advanced extremity melanoma.
    Papadia F; Basso V; Patuzzo R; Maurichi A; Di Florio A; Zardi L; Ventura E; González-Iglesias R; Lovato V; Giovannoni L; Tasciotti A; Neri D; Santinami M; Menssen HD; De Cian F
    J Surg Oncol; 2013 Feb; 107(2):173-9. PubMed ID: 22674435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TNF dose reduction in isolated limb perfusion.
    Grünhagen DJ; de Wilt JH; van Geel AN; Graveland WJ; Verhoef C; Eggermont AM
    Eur J Surg Oncol; 2005 Nov; 31(9):1011-9. PubMed ID: 16099618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020.
    Cornett WR; McCall LM; Petersen RP; Ross MI; Briele HA; Noyes RD; Sussman JJ; Kraybill WG; Kane JM; Alexander HR; Lee JE; Mansfield PF; Pingpank JF; Winchester DJ; White RL; Chadaram V; Herndon JE; Fraker DL; Tyler DS;
    J Clin Oncol; 2006 Sep; 24(25):4196-201. PubMed ID: 16943537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High dose tumor necrosis factor-alpha and melphalan administered via isolated limb perfusion for advanced limb soft tissue sarcoma results in a >90% response rate and limb preservation.
    Gutman M; Inbar M; Lev-Shlush D; Abu-Abid S; Mozes M; Chaitchik S; Meller I; Klausner JM
    Cancer; 1997 Mar; 79(6):1129-37. PubMed ID: 9070490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma.
    Lienard D; Ewalenko P; Delmotte JJ; Renard N; Lejeune FJ
    J Clin Oncol; 1992 Jan; 10(1):52-60. PubMed ID: 1727926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study.
    Fraker DL; Alexander HR; Andrich M; Rosenberg SA
    J Clin Oncol; 1996 Feb; 14(2):479-89. PubMed ID: 8636761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors affecting survival after complete response to isolated limb perfusion in patients with in-transit melanoma.
    Zogakis TG; Bartlett DL; Libutti SK; Liewehr DJ; Steinberg SM; Fraker DL; Alexander HR
    Ann Surg Oncol; 2001 Dec; 8(10):771-8. PubMed ID: 11776490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isolated limb perfusion for melanoma: effectiveness and toxicity of cisplatin compared with that of melphalan and other drugs.
    Thompson JF; Gianoutsos MP
    World J Surg; 1992; 16(2):227-33. PubMed ID: 1561803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors predictive of acute regional toxicity after isolated limb infusion with melphalan and actinomycin D in melanoma patients.
    Kroon HM; Moncrieff M; Kam PC; Thompson JF
    Ann Surg Oncol; 2009 May; 16(5):1184-92. PubMed ID: 19224289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repeat isolated limb perfusion with melphalan for recurrent melanoma of the limbs.
    Klop WM; Vrouenraets BC; van Geel BN; Eggermont AM; Klaase JM; Nieweg OE; Kroon BB
    J Am Coll Surg; 1996 Jun; 182(6):467-72. PubMed ID: 8646345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repeated isolated limb perfusion in melanoma patients with recurrent in-transit metastases.
    Deroose JP; Grünhagen DJ; Eggermont AM; Verhoef C
    Melanoma Res; 2015 Oct; 25(5):427-31. PubMed ID: 26110555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isolated limb perfusion for unresectable melanoma of the extremities.
    Noorda EM; Vrouenraets BC; Nieweg OE; van Geel BN; Eggermont AM; Kroon BB
    Arch Surg; 2004 Nov; 139(11):1237-42. PubMed ID: 15545572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Tumor necrosis factor α and melfalan-based hyperthermic isolated limb perfusion in locally advanced extremity soft tissue sarcomas and melanomas].
    Alegre JF; Duarte M; Sureda González M; Bretcha Boix P; Dussan C; Ballester A; Crespo A; Brugarolas Masllorens A
    Cir Esp; 2012 Feb; 90(2):114-20. PubMed ID: 22225611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of recurrent sarcoma of the extremities by isolated limb perfusion using tumor necrosis factor alpha and melphalan.
    Santinami M; Deraco M; Azzarelli A; Cascinelli F; Chiti A; Costagli V; Inglese MG; Manzi R; Quagliolo V; Rebuffoni G; Santoro N; Vaglini M
    Tumori; 1996; 82(6):579-84. PubMed ID: 9061068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A human melanoma xenograft in a nude rat responds to isolated limb perfusion with TNF plus melphalan.
    Bauer TW; Gutierrez M; Dudrick DJ; Li J; Blair IA; Menon C; Fraker DL
    Surgery; 2003 Apr; 133(4):420-8. PubMed ID: 12717360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.